The Journal of Immunology, Vol 141, Issue 2 519-526, Copyright © 1988 by American Association of Immunologists

ARTICLES

Amplification of IL-2-driven T cell proliferation by recombinant human IL-3 and granulocyte-macrophage colony-stimulating factor

D Santoli, SC Clark, BL Kreider, PA Maslin and G Rovera
Wistar Institute of Anatomy and Biology, Philadelphia, PA 19104.

Two recombinant human preparations of CSF, namely granulocyte- macrophage-CSF (GM-CSF) and IL-3 (multi-CSF), were tested for their ability to stimulate the growth of human freshly separated and in vitro activated lymphocytes. Both CSF independently induced short term proliferation in unfractionated PBL and lectin-stimulated T cells. Despite the great variability among different donors in the magnitude of lymphocyte response to the two growth factors, IL-3 at suboptimal concentrations (10 U/ml) consistently induced a higher proliferative response than did GM-CSF at suboptimal concentrations (5 ng/ml) in all of the preparations tested. When used in combination with IL-2, GM-CSF and, especially, IL-3 significantly potentiated the proliferative responses induced by IL-2 in both unstimulated and mitogen-activated lymphocytes. Dose-response curves using increasing concentrations of IL- 2 and IL-3 and isobologram analysis of these interactions revealed a clear synergy of action between the two growth factors in inducing proliferation of unfractionated PBL, purified T cells, mitogen- activated lymphocytes, and alloantigen-stimulated T cells. In addition to enhancing the short term responsiveness to IL-2, GM-CSF and, especially, IL-3 drastically potentiated the long term growth of non- activated human lymphocytes and of lectin- or Ag-activated T cells in the presence of IL-2. Immunofluorescence analysis indicated a higher expression of activation Ag (anti-Tac receptors and HLA class II Ag) in cultures incubated in the presence of IL-3 either alone or in conjunction with IL-2. The overall data indicate that human GM-CSF and IL-3 can support the growth of cells within the lymphoid lineage and exert potent amplifying effects on IL-2-induced T cell growth in vitro.

This article has been cited by other articles:

				H. Kared, B. Leforban, R. Montandon, A. Renand, E. Layseca Espinosa, L. Chatenoud, Y. Rosenstein, E. Schneider, M. Dy, and F. Zavala Role of GM-CSF in tolerance induction by mobilized hematopoietic progenitors Blood, September 15, 2008; 112(6): 2575 - 2578. [Abstract] [Full Text] [PDF]

				M. Kaspar, E. Trachsel, and D. Neri The Antibody-Mediated Targeted Delivery of Interleukin-15 and GM-CSF to the Tumor Neovasculature Inhibits Tumor Growth and Metastasis Cancer Res., May 15, 2007; 67(10): 4940 - 4948. [Abstract] [Full Text] [PDF]

				S. J. O'Day, P. D. Boasberg, L. Piro, T. S. Kristedja, H.-J. Wang, M. Martin, R. Deck, P. Ames, K. Shinn, H. Kim, et al. Maintenance Biotherapy for Metastatic Melanoma with Interleukin-2 and Granulocyte Macrophage-Colony Stimulating Factor Improves Survival for Patients Responding to Induction Concurrent Biochemotherapy Clin. Cancer Res., September 1, 2002; 8(9): 2775 - 2781. [Abstract] [Full Text] [PDF]

				J. S. Dela Cruz, K. R. Trinh, S. L. Morrison, and M. L. Penichet Recombinant Anti-Human HER2/neu IgG3-(GM-CSF) Fusion Protein Retains Antigen Specificity and Cytokine Function and Demonstrates Antitumor Activity J. Immunol., November 1, 2000; 165(9): 5112 - 5121. [Abstract] [Full Text] [PDF]